HRP20250313T1 - Rekombinantni fsh koji uključuje alfa 2,3- i alfa 2,6-sijalilaciju - Google Patents

Rekombinantni fsh koji uključuje alfa 2,3- i alfa 2,6-sijalilaciju Download PDF

Info

Publication number
HRP20250313T1
HRP20250313T1 HRP20250313TT HRP20250313T HRP20250313T1 HR P20250313 T1 HRP20250313 T1 HR P20250313T1 HR P20250313T T HRP20250313T T HR P20250313TT HR P20250313 T HRP20250313 T HR P20250313T HR P20250313 T1 HRP20250313 T1 HR P20250313T1
Authority
HR
Croatia
Prior art keywords
alpha
sialylation
recombinant fsh
involving
pharmaceutical composition
Prior art date
Application number
HRP20250313TT
Other languages
English (en)
Croatian (hr)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20250313(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of HRP20250313T1 publication Critical patent/HRP20250313T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HRP20250313TT 2008-04-16 2009-04-16 Rekombinantni fsh koji uključuje alfa 2,3- i alfa 2,6-sijalilaciju HRP20250313T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP21212873.0A EP4015527B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
HRP20250313T1 true HRP20250313T1 (hr) 2025-05-09

Family

ID=39717519

Family Applications (5)

Application Number Title Priority Date Filing Date
HRP20250313TT HRP20250313T1 (hr) 2008-04-16 2009-04-16 Rekombinantni fsh koji uključuje alfa 2,3- i alfa 2,6-sijalilaciju
HRP20241187TT HRP20241187T1 (hr) 2008-04-16 2009-04-16 Rekombinantni fsh koji uključuje alfa 2,3- i alfa 2,6-sijalilaciju
HRP20140535AT HRP20140535T1 (hr) 2008-04-16 2009-04-16 Rekombinantni fsh ukljuäśujuä†i alfa 2,3- i alfa 2,6-sialilaciju
HRP20161520TT HRP20161520T1 (hr) 2008-04-16 2016-11-16 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju
HRP20170958TT HRP20170958T1 (hr) 2008-04-16 2017-06-26 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6- sialilaciju

Family Applications After (4)

Application Number Title Priority Date Filing Date
HRP20241187TT HRP20241187T1 (hr) 2008-04-16 2009-04-16 Rekombinantni fsh koji uključuje alfa 2,3- i alfa 2,6-sijalilaciju
HRP20140535AT HRP20140535T1 (hr) 2008-04-16 2009-04-16 Rekombinantni fsh ukljuäśujuä†i alfa 2,3- i alfa 2,6-sialilaciju
HRP20161520TT HRP20161520T1 (hr) 2008-04-16 2016-11-16 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju
HRP20170958TT HRP20170958T1 (hr) 2008-04-16 2017-06-26 Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6- sialilaciju

Country Status (29)

Country Link
US (6) US8951967B2 (enExample)
EP (7) EP3144318B1 (enExample)
JP (7) JP2011519359A (enExample)
KR (5) KR20170110741A (enExample)
CN (3) CN102066414A (enExample)
AR (1) AR071479A1 (enExample)
AU (5) AU2009237479B2 (enExample)
BR (1) BRPI0910461B8 (enExample)
CA (1) CA2725257A1 (enExample)
CY (1) CY1115413T1 (enExample)
DK (6) DK3045471T3 (enExample)
ES (5) ES2629392T3 (enExample)
FI (4) FI4015527T3 (enExample)
FR (3) FR17C1020I2 (enExample)
HR (5) HRP20250313T1 (enExample)
HU (9) HUE071059T2 (enExample)
IL (2) IL208538A (enExample)
LT (8) LT3045471T (enExample)
MX (3) MX2010011343A (enExample)
NO (4) NO2017025I1 (enExample)
NZ (1) NZ588381A (enExample)
PL (6) PL3144318T3 (enExample)
PT (6) PT3098234T (enExample)
RU (3) RU2682270C2 (enExample)
SA (1) SA109300228B1 (enExample)
SI (6) SI2268666T1 (enExample)
TW (1) TWI488640B (enExample)
WO (1) WO2009127826A1 (enExample)
ZA (1) ZA201007373B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HUE025514T2 (en) 2010-09-29 2016-02-29 Ferring Bv Preparation for use in treating infertility
KR101898302B1 (ko) 2010-10-15 2018-09-13 제이씨알 파마 가부시키가이샤 당사슬의 비환원 말단이 만노오스 잔기인 당 단백질의 제조 방법
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6279466B2 (ja) * 2012-04-27 2018-02-14 Ｊｃｒファーマ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
ES2879838T3 (es) 2015-04-17 2021-11-23 Ferring Bv Composición que comprende FSH para el tratamiento de la esterilidad
CN107709350A (zh) * 2015-06-26 2018-02-16 辉凌公司 纯化和/或病毒灭活的方法
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
ES2989511T3 (es) 2017-09-01 2024-11-26 Ferring Bv Composición para la estimulación ovárica controlada
EP4534145A3 (en) 2018-04-30 2025-07-02 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
EP4504236A1 (en) 2022-04-01 2025-02-12 Ferring B.V. Mixed protocol for treatment of infertility
JP2025516966A (ja) 2022-05-26 2025-05-30 フェリング ベスローテン フェンノートシャップ 男性の不妊症の治療のための組成物及び方法
EP4551244A1 (en) 2022-07-08 2025-05-14 Ferring B.V. Compositions and methods for intrauterine insemination (iui)
TW202504578A (zh) 2023-07-20 2025-02-01 荷蘭商輝凌責任有限公司 緩釋載藥微粒

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
DE69823046T2 (de) 1997-01-16 2005-03-31 Neose Technologies, Inc. Praktische in vitro sialylierung von rekombinanten glykpproteinen
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
WO2000067778A1 (en) 1999-05-07 2000-11-16 Applied Research Systems Ars Holding N.V. Gonadotrophins
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
AU2002340562B2 (en) * 2001-10-22 2008-10-23 Merck Serono Sa Compositions of FSH with high sialylation degree and their use for the preparation of medicaments
ATE542904T1 (de) 2001-10-29 2012-02-15 Crucell Holland Bv Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
CA2554968C (en) 2004-02-04 2012-03-27 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016575A1 (en) 2010-08-03 2012-02-09 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HUE025514T2 (en) 2010-09-29 2016-02-29 Ferring Bv Preparation for use in treating infertility
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
EP3131571A1 (en) 2014-04-18 2017-02-22 Glycotope GmbH Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
ES2468318T3 (es) 2014-06-16
EP2268666B1 (en) 2014-03-12
LT3045471T (lt) 2017-07-10
EP3144318A1 (en) 2017-03-22
SA109300228B1 (ar) 2014-04-08
EP3045471B1 (en) 2017-03-29
PL3045471T3 (pl) 2017-10-31
RU2537268C2 (ru) 2014-12-27
HUE033830T2 (en) 2018-01-29
LT2808340T (lt) 2016-11-10
CY1115413T1 (el) 2017-01-04
EP2722339A1 (en) 2014-04-23
TW200948378A (en) 2009-12-01
HUS2500029I1 (hu) 2025-07-28
FR17C1020I2 (fr) 2020-04-10
KR20190092608A (ko) 2019-08-07
HRP20241187T1 (hr) 2024-12-06
AU2017225020B2 (en) 2019-11-14
US9546204B2 (en) 2017-01-17
EP3144318B1 (en) 2020-09-23
US20150065695A1 (en) 2015-03-05
KR20160056960A (ko) 2016-05-20
SI2268666T1 (sl) 2014-07-31
JP7316905B2 (ja) 2023-07-28
SI3098234T1 (sl) 2024-10-30
AU2014203277B2 (en) 2017-04-06
RU2682270C2 (ru) 2019-03-18
CN105906703A (zh) 2016-08-31
US20110105398A1 (en) 2011-05-05
AU2017204259B2 (en) 2017-08-17
US11952407B2 (en) 2024-04-09
CA2725257A1 (en) 2009-10-22
LTPA2017029I1 (lt) 2017-10-10
MX348622B (es) 2017-06-22
FR25C1003I1 (fr) 2025-02-28
NO2017050I1 (no) 2017-09-28
KR20180095140A (ko) 2018-08-24
HUS1700036I1 (hu) 2017-10-30
SI4015527T1 (sl) 2025-05-30
PL2268666T3 (pl) 2014-08-29
FI3098234T3 (fi) 2024-10-31
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
HUE030652T2 (en) 2017-05-29
HUS2500008I1 (hu) 2025-02-28
JP6762916B2 (ja) 2020-09-30
RU2014141994A (ru) 2016-05-10
PT4015527T (pt) 2025-04-10
FR17C1020I1 (enExample) 2020-04-10
BRPI0910461A8 (pt) 2018-10-16
RU2014141994A3 (enExample) 2018-05-28
PT2268666E (pt) 2014-06-25
RU2745557C3 (ru) 2021-12-10
NO2025032I1 (no) 2025-07-14
HUS1700025I1 (hu) 2017-06-28
HK1199039A1 (en) 2015-06-19
FI4015527T3 (fi) 2025-04-29
LT3098234T (lt) 2024-09-10
PT3144318T (pt) 2020-11-04
ES2629392T3 (es) 2017-08-09
BRPI0910461B8 (pt) 2021-05-25
US9771407B2 (en) 2017-09-26
ES2989729T3 (es) 2024-11-27
AU2017225020A1 (en) 2017-09-28
NO2025006I1 (no) 2025-01-16
RU2745557C1 (ru) 2021-03-29
JP6486310B2 (ja) 2019-03-20
FR25C1025I1 (fr) 2025-09-19
NZ588381A (en) 2012-05-25
AU2014203277A1 (en) 2014-07-24
EP2268666A1 (en) 2011-01-05
JP2011519359A (ja) 2011-07-07
RU2010141908A (ru) 2012-05-27
EP3098234B1 (en) 2024-07-31
BRPI0910461B1 (pt) 2021-02-23
DK3144318T3 (da) 2020-12-07
EP4015527B1 (en) 2025-01-22
EP2808340A1 (en) 2014-12-03
LT4015527T (lt) 2025-04-10
JP2015120696A (ja) 2015-07-02
LTPA2025505I1 (enExample) 2025-02-10
EP4015527A1 (en) 2022-06-22
DK2808340T3 (en) 2016-12-05
HUE068565T2 (hu) 2025-01-28
US20160347811A1 (en) 2016-12-01
EP3098234A1 (en) 2016-11-30
FIC20250003I1 (fi) 2025-01-15
DK2268666T3 (da) 2014-05-12
AU2009237479B2 (en) 2014-05-15
HRP20161520T1 (hr) 2016-12-30
AU2017204258B2 (en) 2017-08-17
KR102108377B1 (ko) 2020-05-08
HK1146284A1 (en) 2011-05-20
KR20110005863A (ko) 2011-01-19
ZA201007373B (en) 2011-06-29
KR20170110741A (ko) 2017-10-11
CN102066414A (zh) 2011-05-18
PT3098234T (pt) 2024-10-21
JP2020040956A (ja) 2020-03-19
AU2017204258A1 (en) 2017-07-20
AU2009237479A1 (en) 2009-10-22
KR101622944B1 (ko) 2016-05-23
JP2017060476A (ja) 2017-03-30
CN105906702A (zh) 2016-08-31
EP3045471A1 (en) 2016-07-20
HUS1700024I1 (hu) 2017-06-28
US20180079794A1 (en) 2018-03-22
PL3144318T3 (pl) 2021-02-08
BRPI0910461A2 (pt) 2018-03-27
IL208538A (en) 2014-03-31
JP2022031652A (ja) 2022-02-22
EP2808340B1 (en) 2016-08-17
US20210332099A1 (en) 2021-10-28
TWI488640B (zh) 2015-06-21
AU2017204259A1 (en) 2017-07-20
US10995128B2 (en) 2021-05-04
NO2017025I1 (no) 2017-06-06
ES3023526T3 (en) 2025-06-02
AU2014203277C1 (en) 2017-07-27
JP2018021037A (ja) 2018-02-08
DK4015527T3 (da) 2025-04-14
SI3045471T1 (sl) 2017-07-31
SI3144318T1 (sl) 2020-12-31
FIC20250025I1 (fi) 2025-07-11
LTPA2017018I1 (lt) 2017-06-26
HUE071059T2 (hu) 2025-07-28
HRP20170958T1 (hr) 2017-09-22
WO2009127826A1 (en) 2009-10-22
IL230571A (en) 2015-11-30
LTPA2025525I1 (enExample) 2025-07-25
PL2808340T3 (pl) 2017-02-28
US20240327487A1 (en) 2024-10-03
MX355457B (es) 2018-04-19
PT3045471T (pt) 2017-06-14
PL3098234T3 (pl) 2025-01-07
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
PT2808340T (pt) 2016-11-21
DK3045471T3 (en) 2017-06-26
JP2024038000A (ja) 2024-03-19
SI2808340T1 (sl) 2016-12-30
AR071479A1 (es) 2010-06-23
IL208538A0 (en) 2010-12-30
DK3098234T3 (da) 2024-10-21
HUE030652T4 (en) 2017-09-28
US8951967B2 (en) 2015-02-10

Similar Documents

Publication Publication Date Title
HRP20250313T1 (hr) Rekombinantni fsh koji uključuje alfa 2,3- i alfa 2,6-sijalilaciju
CL2013001410A1 (es) Variante polipeptidica de fgf21; multimero que la comprende; composicion farmaceutica que la comprende; y su uso para tratar uno o mas trastornos asociados a fgf21.
PT2341142E (pt) Péptido wt1 restringido a hla-a*1101 e composição farmacêutica compreendendo o mesmo
CL2012001710A1 (es) Anticuerpo aislado que se enlaza selectivamente a hepcidina-25 humana y cuyas hcvr y lcvr tienen las secuencias de aminoácido sec id nos:150 y 124; polinucleótido, vector; célula hospedadora; uso en el tratamiento y/o prevención de anemia; procedimiento de producción y composición farmacéutica (div. de sol. 3190-08).
JP2010539123A5 (enExample)
IL232409A0 (en) 3033*a-hla- reduced 1wt peptide and pharmaceutical compound containing it
SI2432798T1 (sl) Derivat 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-arila, postopki izdelave in uporaba pri zdravljenju bolezni
PL3225248T3 (pl) Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
IL201791A0 (en) Modified interferon beta polypeptides and their uses
BR112012011780A2 (pt) peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
CA122665S (en) Trigger latch
HRP20200875T8 (hr) Inhibitorni peptidi porijeklom od aktivirajućeg receptora eksprimiranog na mijeloidnim stanicama-1 (trem-1)-sličnog transkripta 1 (tlt-1) i nihove upotrebe
EP2488167A4 (en) INGREDIENTS INCLUDED IN A CARBOHYDRATE FOR ACTIVE INJECTION AND ARTICLE THEREWITH
EP3021857A4 (en) BIOMATERIALS WITH HYALURONIC ACID BINDING PEPTIDES AND EXTRACELLULAR MATRIX-BONDING PEPTIDES FOR HYALURONIC ACID TREATMENT AND TISSUE-BREEDING APPLICATIONS
PL2266619T3 (pl) Kompozycja farmaceutyczna na bazie środków chroniących wątrobę i środków prebiotycznych, ich wytwarzanie i zastosowanie
CL2008000092A1 (es) Compuestos derivados de 3-cianopiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compustos; y su uso en el tratamiento del transtorno de la agregacion plaquetaria.
HRP20201688T1 (hr) Rekombinantni fsh koji ukjlučuje alfa 2,3- i alfa 2,6-sialilaciju
EP2275437A4 (en) POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THE POLYPEPTIDE
HK1202554A1 (en) Cladosporium peptides
Rohrbach Trendovi konjukturnih skokova
PL1877035T3 (pl) Kompozycja farmaceutyczna i postać galenowa szybko rozpadająca się w jamie ustnej oraz sposób jej wytwarzania
RU2007117634A (ru) Композиции на основе элагеновой кислоты
ITAR20070032A1 (it) Trasbordatore per la movimentazione di unita' di carico da e su vagoni ferroviari sotto linea elettrica.
TH96408B (th) อุปกรณ์สำหรับเชื่อมต่อ